{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
benzoyl peroxide
to a specific field?
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
EnLyte Extra-LN by Jaymac Pharmacueticals LLC
Source URL:
First approved in 2024
Source:
Biopar delta-FORTE by Jaymac Pharma
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
First approved in 2023
Source:
NDA216023
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Flotufolastat F 18 (POSLUMA®) is an 18F-labelled radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted imaging agent being developed by Blue Earth Diagnostics, a subsidiary of Bracco Imaging, for prostate cancer imaging. In May 2023, flotufolastat F 18 received its first approval in the USA as a radioactive diagnostic agent for positron emission tomography (PET) of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a beta emitting radionuclide that can be detected using positron emission tomography.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dimethyl succinate is the inactive analog of dimethyl fumarate. Dimethyl succinate has a pleasant, ethereal, winey odor and a fruity, winey, and burning flavor. It is used in foods as a flavoring ingredient. Dimethyl succinate was found at increased concentrations in the culture medium of the lung cancer cell line A549 and in the urine of mice implanted with A549 cells. Dimethyl succinate could be used to prolong the insulinotropic action of GLP-1 in the treatment of type-2 diabetes and it may represent a novel therapeutic approach in endotoxemia and multiple-organ failure.
Status:
Possibly Marketed Outside US
Source:
21 CFR 350
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 350
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
First approved in 2018
Source:
Peraflu D by minam medical
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Peracetic acid, also known as peroxyacetic acid, is an organic peroxide used an an antimicrobial agent. It is commonly utlized as a medical instrument and food industry disinfectant. Peracetic acid is also used in epoxidation of various alkenes, converting carbon–carbon double bonds into oxiranes. It is a strong oxidizing agent that can cause irritation to skin and respiratory tract.
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
